
New Hampshire COVID-19 Education and Child Care Partner Call

June 1, 2022





COVID-19 Vaccine Updates




COVID-19 Vaccination For Children 5-11 Years

- Children 5-11 years of age are now recommended to receive a booster dose after completion of their primary series:
 - Children who ARE moderately-severely immunocompromised are recommended to get a booster dose starting at least 3 months after completion of a 3-dose primary series
 - Children who are NOT moderately-severely immunocompromised are recommended to get a booster dose starting at least 5 months after completion of a 2-dose primary series
- CDC is also now formally recommending ("should receive") a second booster dose for:
 - People 50 years of age or older (based on age alone)
 - People 12-49 years of age who are moderately-severely immunocompromised.



COVID-19 Vaccination Schedule for Most People



COVID-19 Vaccination Schedule for People Who Are Moderately or Severely Immunocompromised

Number and intervals of COVID-19 vaccine doses




Table 1. Immunization schedule for persons 5 years of age and older

Туре	Recipient Age	Product	Persons Who ARE NOT Moderately or Severely Immunocompromised		Persons Who ARE Moderately or Severely Immunocompromised	
			Primary Series*	Booster Dose†‡	Primary Series*	Booster Dose ^{†‡}
mRNA vaccine	5–11 years	Pfizer-BioNTech Ages: 5–11 years Orange cap	2 doses. Separate: Dose 1 and 2 by at least 3 weeks.	Booster dose 1: At least 5 months after Dose 2 Booster dose 2: N/A	3 doses. Separate: Dose 1 and 2 by at least 3 weeks. Dose 2 and 3 by at least 4 weeks.	Booster dose 1: At least 3 months after Dose 2 Booster dose 2: N/A
	12–17 years	Pfizer-BioNTech Ages: 12 years and older Gray cap or Purple cap	2 doses. Separate: Dose 1 and 2 by at least 3 - 8 weeks.§	Booster dose 1: At least 5 months after Dose 2 Booster dose 2: N/A	3 doses. Separate: Dose 1 and 2 by at least 3 weeks. Dose 2 and 3 by at least 4 weeks.	Booster dose 1: At least 3 months after the previous dose Booster dose 2: At least 4 months after booster dose 1
	18 years and older	Pfizer-BioNTech Ages: 12 years and older Gray cap or Purple cap	2 doses. Separate: Dose 1 and 2 by at least 3 - 8 weeks.§	Booster dose 1: At least 5 months after Dose 2 Booster dose 2: At least 4 months after booster dose 1 for persons ages 50 years and older	3 doses. Separate: Dose 1 and 2 by at least 3 weeks. Dose 2 and 3 by at least 4 weeks.	Booster dose 1: At least 3 months after the previous dose Booster dose 2: At least 4 months after booster dose 1
		Moderna	2 doses. Separate: Dose 1 and 2 by at least 4 - 8 weeks.§	Booster dose 1: At least 5 months after Dose 2 Booster dose 2: At least 4 months after booster dose 1 for persons ages 50 years and older	3 doses. Separate: Dose 1 and 2 by at least 4 weeks. Dose 2 and 3 by at least 4 weeks.	Booster dose 1: At least 3 months after the previous dose Booster dose 2: At least 4 months after booster dose 1
Viral vector vaccine	18 years and older	Janssen [¶]	1 dose	Booster dose 1: At least 2 months after the primary series dose Booster dose 2**: At least 4 months after previous dose for persons 50 years of age and older. (mRNA vaccine only)	2 doses. Separate: Dose 1 and 2 ^{††} by at least 28 days	Booster dose 1: At least 2 months after the previous dose Booster dose 2: At least 4 months after the previous dose (mRNA vaccine only)

Vaccines and Related Biological Products Advisory Committee June 14-15, 2022 Meeting Announcement

JUNE 14 - 15, 2022

f Share **y** Tweet **in** Linkedin **y** Email **⊕** Print

On This Page

• Meeting Information

Date: June 14 - 15, 2022

Day1: Tue, Jun 14 8:30 AM - 5:00 PM ET **Day2:** Wed, Jun 15 8:30 AM - 5:00 PM ET

- 6/14/2022 Day 1
 - Youtube: https://youtu.be/GbNpaZeDPiA
- 6/15/2022 Day 2
 - ∘ Youtube: https://youtu.be/Ixm4UmldTGQ D



FDA VRBPAC Meeting June 14-15

"On June 14, 2022... the committee will meet in open session to discuss amending the EUA of the Moderna COVID-19 mRNA vaccine to include the administration of the primary series to children and adolescents 6 years through 17 years of age."

"On June 15, 2022... the committee will meet in open session to discuss amending the EUA of the Moderna COVID-19 mRNA vaccine to include the administration of the primary series to infants and children 6 months through 5 years of age, and also to discuss amending the EUA of the Pfizer-BioNTech COVID-19 mRNA vaccine to include the administration of the primary series to infants and children 6 months through 4 years of age."



Covid-19 Testing Resources and SASS Program Updates



Overview

- BinaxNOW Antigen Tests
- Over-the-counter (OTC) antigen tests
- SASS Program Updates



BinaxNOW Antigen Tests

► Schools may order BinaxNOW Covid-19 antigen tests

- A CLIA ID & medical direction are <u>required</u> to order and use these tests
 - SASS program fulfills the medical direction and CLIA ID requirements for participating schools
- Must be used on-site
 - Because of the type of antigen test, these tests must used at the school and should not be sent home with staff or students
- Supplies are based upon availability
 - 6 boxes (40 tests/box) are available per school monthly
 - Click here to order tests





Flowflex Over-the-counter (OTC) Covid-19 Tests

OTC antigen tests for schools and daycares

- Program is live & new orders are being accepted
- Orders that were previously received will be fulfilled
- Medical direction and CLIA ID are <u>not</u> required
- Tests may be used within the facility or distributed to students & staff

Ordering Process

- Use this <u>link</u> to order free tests
 - Orders will be accepted based upon supply availability
- Pick-up location: DHHS Warehouse, Concord
 - A DHHS staff member will coordinate an appointment to pick-up these tests





Future SASS Plans

Enrollment

- Schools may enroll by completing this <u>survey</u>
- Currently enrolled schools will automatically be re-enrolled for the new school year
- Schools that want to withdraw enrollment should email <u>SASS@dhhs.nh.gov</u>

PCR Testing

- PCR testing will be available
- We anticipate using the same vendors & specimen collection processes
- Medical direction and CLIA ID are required for PCR testing
 - Requirement is fulfilled through the SASS program
- Additional updates will be provided through the Department of Education (DoE) once administrative processes are complete



Future SASS Plans (continued)

BinaxNOW Antigen Testing Program

- Medical direction & CLIA ID are required
- SASS program fulfills the medical direction and CLIA ID requirements for participating schools
- Tests are available to order through this <u>link</u>
- Pick-up is at the DHHS warehouse in Concord
- Tests must be used at the school and should <u>not</u> be sent home with staff or students

Flowflex OTC Antigen Testing Program

- OTC antigen tests available for schools that don't enroll in the SASS program
- Medical direction & CLIA ID are <u>not required</u>
- Tests should be ordered using this <u>link</u>

Please email SASS@dhhs.nh.gov for questions related to the SASS program



Other Updates



CDC's Updated Guidance for K-12 Schools and Child Care Programs

Operational Guidance for K-12 Schools and Early Care and Education Programs to Support Safe In-Person Learning

Updated May 27, 2022

Languages ▼

Print

Introduction

Schools and early care and education (ECE) programs are an important part of the infrastructure of communities as they provide safe, supportive learning environments for students and children and enable parents and caregivers to be at work. Schools and ECE programs like Head Start also provide critical services that help to mitigate health disparities, such as school lunch programs, and social, physical, behavioral, and mental health services. This guidance can help K-12 school and ECE program administrators support safe, in-person learning for K-12 schools, and keep ECE programs open, while managing the spread of COVID-19. Based on the COVID-19 Community Levels, this guidance provides flexibility so schools and ECE programs can adapt to changing local situations, including periods of increased community health impacts from COVID-19.

On this Page

Introduction

Strategies for Everyday Operations

COVID-19 Community Levels and Associated Prevention Strategies

Considerations for Prioritizing Strategies



Help Promote COVID-19 Vaccines for Children and Adolescents

Resources to Promote the COVID-19 Vaccine for Children & Teens









On This Page

Social Media Graphics and Posters

Videos

Customizable COVID-19 Vaccination Letter Template

Resources for Parents and Caregivers

Resources for Vaccine Providers and Healthcare Professionals

Resources for Schools and Early Care and Education Programs

Additional External Partner Resources



Help Promote COVID-19 Vaccines for Children and Adolescents

Social Media Toolkit: COVID-19 Vaccines for Children/Teens

Updated Apr. 5, 2022

Languages *

Print

Sample Message

Parents & Caregivers: Your children count on you to keep them safe and healthy. If you have questions or concerns about your child receiving the #COVID19 vaccine, talk to your healthcare provider. Learn more:

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/children-teens.html #SleeveUp



Call Schedule

- Today's webinar is the LAST in the education and child care partner call series
- There is no plan to continue these calls over the summer or next school year
- We will continue our monthly Thursday partner calls for healthcare providers and other public health partners
- Zoom webinar poll...



Q&A

